Skip to Content

Neon Therapeutics, Inc. (NASDAQ: NTGN)

Merger

  • Date:
  • 1/16/2020
  • Company Name:
  • Neon Therapeutics, Inc.
  • Stock Symbol:
  • NTGN
  • Company Name - Buyer:
  • BioNTech sE
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 1/16/2020

Case Finder

Locate any case using the tools below.

NEW YORK, January 16, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Neon Therapeutics, Inc. (NASDAQ: NTGN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s proposed sale to BioNTech SE

On January 16, 2020 Neon Therapeutics announced that it had signed an agreement to be acquired by BioNTech in a deal worth approximately $67 million. Per the merger agreement Neon Therapeutics stockholders will receive 0.063 shares of BioNTech common stock for each share of Neon Therapeutics common stock owned. The deal is scheduled to close in second quarter of-2020.

Bragar Eagel & Squire is concerned that Neon Therapeutics’ board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Neon Therapeutics stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Neon Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: